Acurx Pharmaceuticals Secures Funding for Recurrent C. difficile Trials — Acurx Pharmaceuticals, Inc.

Event summary

Acurx raised $2.5 million in a registered direct offering and $0.8 million under an equity line of credit, bringing total cash to $10.7 million as of Q2 2026.
FDA provided favorable guidance on a single Phase 3 study for ibezapolstat's New Drug Application (NDA) in August 2026.
Acurx secured new patents in Japan and Mexico, expanding its intellectual property portfolio to six U.S. patents and ten international patents.
The company received FDA conditional acceptance and USPTO trademark allowance for the proprietary name of ibezapolstat for treating C. difficile infection.

The big picture

Acurx Pharmaceuticals is positioning itself as a key player in the development of novel antibiotics for difficult-to-treat bacterial infections. The company's focus on DNA polymerase IIIC inhibitors, particularly ibezapolstat, aims to address the urgent threat of C. difficile infections, which have been designated as an urgent threat by the CDC. With favorable regulatory guidance and a strengthened intellectual property portfolio, Acurx is poised to advance its clinical trials and potentially change the treatment paradigm for recurrent C. difficile infections.

What we're watching

Clinical Trial Progress: The success of the exploratory clinical trial in recurrent C. difficile infection will determine ibezapolstat's potential to shift treatment paradigms.
Regulatory Approval: Whether Acurx can secure FDA and EMA approvals for ibezapolstat, given the favorable guidance received in August 2026.
Financial Sustainability: The pace at which Acurx can sustain its financial resources to conduct further clinical trials and expand its pipeline.